Intellia Therapeutics (NASDAQ:NTLA) Price Target Lowered to $64.00 at Stifel Nicolaus

Intellia Therapeutics (NASDAQ:NTLA) had its target price reduced by Stifel Nicolaus from $80.00 to $64.00 in a research report sent to investors on Wednesday, Benzinga reports. They currently have a buy rating on the stock.

A number of other analysts also recently commented on NTLA. Evercore ISI raised Intellia Therapeutics to a strong-buy rating in a research note on Friday, August 9th. JPMorgan Chase & Co. dropped their price objective on Intellia Therapeutics from $61.00 to $55.00 and set an overweight rating on the stock in a research note on Monday, August 12th. Canaccord Genuity Group reissued a buy rating and issued a $73.00 price objective on shares of Intellia Therapeutics in a research note on Thursday, June 27th. StockNews.com raised Intellia Therapeutics to a sell rating in a research note on Thursday, June 27th. Finally, Cantor Fitzgerald reissued an overweight rating and issued a $65.00 price objective on shares of Intellia Therapeutics in a research note on Monday, June 24th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of Moderate Buy and a consensus price target of $61.77.

Intellia Therapeutics Price Performance

Shares of Intellia Therapeutics stock opened at $20.24 on Wednesday. The business’s fifty day moving average price is $23.47 and its two-hundred day moving average price is $24.57. The company has a market capitalization of $2.06 billion, a P/E ratio of -3.78 and a beta of 1.77. Intellia Therapeutics has a 1-year low of $19.21 and a 1-year high of $38.71.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The business had revenue of $7.00 million during the quarter, compared to analysts’ expectations of $19.68 million. Intellia Therapeutics’s quarterly revenue was down 48.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.40) earnings per share. On average, research analysts expect that Intellia Therapeutics will post -5.19 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Sanctuary Advisors LLC purchased a new position in shares of Intellia Therapeutics during the second quarter valued at $449,000. Algert Global LLC grew its holdings in shares of Intellia Therapeutics by 307.0% during the second quarter. Algert Global LLC now owns 68,372 shares of the company’s stock valued at $1,530,000 after buying an additional 51,572 shares in the last quarter. Scientech Research LLC grew its holdings in shares of Intellia Therapeutics by 133.0% during the second quarter. Scientech Research LLC now owns 47,101 shares of the company’s stock valued at $1,054,000 after buying an additional 26,884 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Intellia Therapeutics by 763.5% during the second quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock valued at $39,000 after buying an additional 1,550 shares in the last quarter. Finally, Ensign Peak Advisors Inc grew its holdings in shares of Intellia Therapeutics by 23.5% during the second quarter. Ensign Peak Advisors Inc now owns 36,019 shares of the company’s stock valued at $806,000 after buying an additional 6,850 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.